ランキング
価格
はじめての方へ
ログイン
無料体験
米国企業
Syros Pharmaceuticals, Inc.
Syros Pharmaceuticals, Inc.
SYRS
時価総額
$4100.6万
PER
マイリストに追加
マイリストに追加
サマリーテーブルに戻る
十億
百万
千
USD
年次
四半期
Download CSV
損益計算書
バランスシート
キャッシュフロー
2016年
12月31日
2017年
12月31日
2018年
12月31日
2019年
12月31日
2020年
12月31日
2021年
12月31日
2022年
12月31日
Net loss
-
-
-62
-75
-84
-87
-95
Depreciation and amortization
1
2
2
3
3
3
3
Amortization of right-of-use asset
-
-
-
0
0
0
0
Transaction costs allocated to warrants issued in connection with private placement
-
-
-
-
-
-
5
Loss on disposal of fixed assets
-0
-
-
-
-
-
-
Stock-based compensation expense
4
4
7
10
11
10
11
Fair Value Adjustment of Warrants
-
-
-
-
0
-17
-43
Net amortization of premiums and discounts on marketable securities
-0
0
1
1
0
-0
-0
Amortization of debt-discount and accretion of deferred debt costs
-
-
-
-
0
1
1
Prepaid expenses and other current assets
1
-0
1
1
-0
1
3
Accounts receivable
0
-1
-
20
-20
-0
-
Contract assets
-
-
-
-
2
1
-1
Other long-term assets
0
0
0
-
1
1
2
Accounts payable
-0
0
1
1
-1
0
3
Accrued expenses
4
4
4
-4
1
5
2
Deferred revenue
-
-
10
18
-6
-12
-6
Proceeds for tenant improvement incentive from landlord
-
-
-
7
2
-
-
Operating lease asset and liabilities
-
-
-
-1
0
1
1
Net cash used in operating activities
-
-45
-40
-60
-57
-100
-123
Purchases of property and equipment
2
1
1
13
3
1
1
Proceeds from Sale of Property, Plant, and Equipment
-
-
0
0
-
-
-
Purchases of marketable securities
25
42
97
108
-
51
-
Maturities of marketable securities
-
27
88
109
50
-
68
Net cash (used in) provided by investing activities
-
-16
-11
-12
47
-53
67
Payments on financing lease obligations
-
-
-
-
-
0
0
Proceeds from Stock Plans
-
-
-
0
0
0
0
Proceeds from Stock Options Exercised
-
-
-
-
-
-
0
Payment to creditor related to debt modification
-
-
-
-
-
-
0
Gross proceeds from common stock
0
32
69
1
12
-
-
Proceeds from Debt, Net of Issuance Costs
-
-
-
-
40
-
-
Cash and cash equivalents acquired in connection with merger,net of issuance costs paid
-
-
-
-
-
-
12
Proceeds from issuance of common stock and accompanying warrants and pre-funded warrants in private placement, net of issuance costs
-
-
-
-
90
-
120
Proceeds From Issuance Of Common Stock And Warrants In Public Offering Net Of Issuance Costs
-
-
-
-
-
70
-
Cash paid in lieu of fractional shares due to the reverse stock split
-
-
-
-
-
-
0
Proceeds From Issuance Of Convertible Preferred Stock And Accompanying Warrants In Public Offering Net Of Issuance Costs
-
-
-
5
-
-
-
Payment of issuance costs related to out of period offering
-
-
-
-
-
0
0
Net cash provided by financing activities
-
34
69
66
143
71
131
Net increase (decrease) in cash, cash equivalents and restricted cash
-
-
18
-6
132
-82
75
Cash paid for interest
-
0
0
0
2
3
3
Cash paid for tax
-
-
-
0
0
-
-
Capital Expenditures Incurred but Not yet Paid
0
0
0
2
0
0
-
Asset acquired under operating lease
-
-
-
16
-
-
-
Assets acquired under financing lease
-
-
-
1
-
-
-
Deferred debt financing costs incurred but unpaid as of period end
-
-
-
0
0
0
-
Offering Cost Incurred But Not Yet Paid
-
0
-
0
0
0
0